Terminated PHASE2 INTERVENTIONAL 1-arm NCT02398825

Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

Optimizing Ponatinib USe (OPUS). A GIMEMA Phase 2 Study of the Activity and Risk Profile of Ponatinib, 30 mg Once Daily, in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients Resistant to Imatinib

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Conditions Adults Chronic Myeloid Leukemia Chronic Phase

Interventions Ponatinib

Updated 11 times since 2017 Last updated: Jan 15, 2025 Started: Jun 23, 2016 Primary completion: Nov 13, 2020 Completion: Dec 27, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low enrollment rate

Other terminated trials from Gruppo Italiano Malattie EMatologiche dell'Adulto

See all terminations from Gruppo Italiano Malattie EMatologiche dell'Adulto

A PHASE2 clinical study on Adults and Chronic Myeloid Leukemia, this trial is terminated or withdrawn. The trial is conducted by Gruppo Italiano Malattie EMatologiche dell'Adulto and has accumulated 11 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Feb 2025 — Sep 2025 [monthly]

Terminated PHASE2

Status: Unknown → Terminated
Sep 2024 — Feb 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Sep 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status

▶ Show 6 earlier versions

Feb 2022 — Sep 2023 [monthly]

Active Not Recruiting PHASE2
Sep 2021 — Feb 2022 [monthly]

Active Not Recruiting PHASE2

Status: Unknown Status → Active Not Recruiting
Jan 2021 — Sep 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Jan 2021 [monthly]

Recruiting PHASE2
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE2

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gruppo Italiano Malattie EMatologiche dell'Adulto

Data source: Gruppo Italiano Malattie EMatologiche dell'Adulto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Ancona, Italy , Bologna, Italy , Brescia, Italy , Cagliari, Italy , Catania, Italy , Catanzaro, Italy , Cona, Italy , Cuneo, Italy , Genova, Italy and 20 more locations